Incyte Genomics Inc
INCY Real Time Price USDRecent trades of INCY by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in INCY holdings by institutional investors
Quarterly net insider trading by INCY's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$750,000 Jul 20, 2026 Issue: Medicare/Medicaid
-
$480,000 Apr 20, 2026 Issue: Medicare/Medicaid
-
$530,000 Jan 20, 2026 Issue: Medicare/Medicaid
-
$330,000 Oct 20, 2025 Issue: Medicare/Medicaid
-
$520,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$240,000 Apr 21, 2025 Issue: Medicare/Medicaid
-
$350,000 Feb 21, 2025 Issue: Medicare/Medicaid
-
$220,000 Oct 21, 2024 Issue: Medicare/Medicaid
-
$300,000 Jul 22, 2024 Issue: Medicare/Medicaid
-
$460,000 Apr 22, 2024 Issue: Medicare/Medicaid
-
$360,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$220,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$180,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid
-
$220,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid
-
$200,000 Jul 21, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid
-
$280,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$110,000 Jan 21, 2022 Issue: MEDICARE/MEDICAID
-
$190,000 Oct 20, 2021 Issue: MEDICARE/MEDICAID
-
$500,000 Jul 20, 2021 Issue: MEDICARE/MEDICAID
-
$200,000 Apr 20, 2021 Issue: MEDICARE/MEDICAID
-
$50,000 Jan 21, 2021 Issue: Health Issues
-
$50,000 Jan 20, 2021 Issue: None
-
$20,000 Jan 19, 2021 Issue: None
-
$50,000 Oct 20, 2020 Issue: Health Issues
-
$50,000 Oct 20, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Jul 20, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Jul 20, 2020 Issue: Medicare/Medicaid
-
$50,000 Apr 27, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Apr 17, 2020 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: MEDICARE/MEDICAID
-
$30,000 Jan 18, 2020 Issue: Medicare/Medicaid
-
$20,000 Mar 26, 2003 Issue: Copyright/Patent/Trademark
-
$20,000 Aug 22, 2002 Issue: Copyright/Patent/Trademark
-
$20,000 Mar 14, 2002 Issue: Copyright/Patent/Trademark
-
$60,000 Feb 20, 2002 Issue: None
-
$20,000 Sep 28, 2001 Issue: Copyright/Patent/Trademark
-
$60,000 Feb 15, 2000 Issue: Medical/Disease Research/Clinical Labs
-
$40,000 Aug 16, 1999 Issue: Medical/Disease Research/Clinical Labs
INCY Estimated quarterly lobbying spending
INCY Revenue by Segment or Geography
New INCY patent grants
-
Patent Title: Bicyclic amine cdk12 inhibitors Jun. 02, 2026
-
Patent Title: Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases Jun. 02, 2026
-
Patent Title: Methods for predicting therapeutic benefit of anti-cd19 therapy in patients May. 19, 2026
-
Patent Title: Topical formulation for a jak inhibitor May. 12, 2026
-
Patent Title: Tetracyclic compounds as dgk inhibitors Apr. 14, 2026
-
Patent Title: Tetracyclic compounds as dgk inhibitors Apr. 14, 2026
-
Patent Title: Tricyclic compounds as inhibitors of kras Apr. 14, 2026
-
Patent Title: Ruxolitinib formulation for reduction of itch in atopic dermatitis Mar. 31, 2026
-
Patent Title: Topical formulation for a jak inhibitor Mar. 03, 2026
-
Patent Title: Tricyclic heterocycles as fgfr inhibitors Feb. 17, 2026
-
Patent Title: N-substituted piperidines and their use as pharmaceuticals Oct. 16, 2012
-
Patent Title: Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 Oct. 02, 2012
-
Patent Title: Piperazinylpiperidine derivatives as chemokine receptor antagonists Sep. 18, 2012
-
Patent Title: Human β-adrenergic receptor kinase polypeptide and methods Sep. 11, 2012
-
Patent Title: Human transmembrane proteins Jun. 26, 2012
-
Patent Title: Lactam compounds and methods of using the same Jun. 05, 2012
-
Patent Title: Azetidine and cyclobutane derivatives as jak inhibitors Apr. 17, 2012
-
Patent Title: Polynucleotides encoding signal peptide-containing molecules Apr. 10, 2012
-
Patent Title: Triazolotriazines as kinase inhibitors Mar. 27, 2012
-
Patent Title: Lactam compounds and their use as pharmaceuticals Feb. 07, 2012
-
Patent Title: 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Jan. 03, 2012
-
Patent Title: Compositions, methods and kits relating to her-2 cleavage Jan. 03, 2012
-
Patent Title: N-substituted piperidines and their use as pharmaceuticals Dec. 06, 2011
-
Patent Title: Amido compounds and their use as pharmaceuticals Nov. 15, 2011
-
Patent Title: Methods for detecting expression of human protease molecules Oct. 25, 2011
-
Patent Title: Purinone derivatives as hm74a agonists Oct. 18, 2011
-
Patent Title: Aza spiro alkane derivatives as inhibitors of metalloproteases Oct. 18, 2011
-
Patent Title: Modulators of indoleamine 2,3-dioxygenase and methods of using the same Oct. 11, 2011
-
Patent Title: Methods of screening for compounds that modulate the activity of adec, a chemokine expressed in inflamed adenoid Aug. 30, 2011
-
Patent Title: Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same Aug. 16, 2011
-
Patent Title: 3-aminopyrrolidine derivatives as modulators of chemokine receptors Jul. 26, 2011
-
Patent Title: Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases Jul. 05, 2011
-
Patent Title: Vesicle trafficking proteins May. 24, 2011
-
Patent Title: Antibody that binds human eosinophil-derived basic protein Apr. 26, 2011
-
Patent Title: Triazolotriazines as kinase inhibitors Mar. 29, 2011
-
Patent Title: Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases Mar. 22, 2011
-
Patent Title: Purinone derivatives as hm74a agonists Mar. 08, 2011
-
Patent Title: Purinone derivatives as hm74a agonists Jan. 04, 2011
-
Patent Title: Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same Nov. 23, 2010
-
Patent Title: Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile Nov. 16, 2010
-
Patent Title: 3-aminopyrrolidine derivatives as modulators of chemokine receptors Nov. 16, 2010
-
Patent Title: Human β-adrenergic receptor kinase nucleic acid molecule Nov. 09, 2010
-
Patent Title: Amido compounds and their use as pharmaceuticals Aug. 17, 2010
-
Patent Title: Imidazotriazines and imidazopyrimidines as kinase inhibitors Aug. 03, 2010
-
Patent Title: Aza spiro alkane derivatives as inhibitors of metalloproteases May. 25, 2010
-
Patent Title: Methods of treatment with anitbodies to a chemokine expressed in inflamed adenoid May. 04, 2010
-
Patent Title: 3-aminocyclopentanecrboxamides as modulators of chemokine receptors Apr. 20, 2010
-
Patent Title: 2-methylprop anamides and their use as pharmaceuticals Mar. 30, 2010
-
Patent Title: Triazolotriazines as kinase inhibitors Mar. 23, 2010
-
Patent Title: Piperazinylpiperidine derivatives as chemokine receptor antagonists Mar. 16, 2010
Federal grants, loans, and purchases
- $499,918 2026-03-27 00:00:00 Agency: Department of Veterans Affairs
- $541,104 2025-04-28 00:00:00 Agency: Department of Veterans Affairs
- $119,619 2024-07-02 00:00:00 Agency: Department of Veterans Affairs
- $541,104 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $13,291 2024-03-15 00:00:00 Agency: Department of Veterans Affairs
- $13,291 2024-01-26 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2024-01-12 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-12-12 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-11-29 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-11-03 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-09-25 00:00:00 Agency: Department of Veterans Affairs
- $12,874 2023-07-28 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-06-13 00:00:00 Agency: Department of Veterans Affairs
- $12,874 2023-05-02 00:00:00 Agency: Department of Veterans Affairs
- $12,812 2023-04-20 00:00:00 Agency: Department of Veterans Affairs
- $675,000 2023-04-11 00:00:00 Agency: Department of Veterans Affairs
- $38,199 2023-03-15 00:00:00 Agency: Department of Veterans Affairs
- $82,626 2022-06-30 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $76,351 2022-04-27 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $499,918 2022-02-18 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2022-02-04 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded to INCY from public contracts
Recent insights relating to INCY
Recent picks made for INCY stock on CNBC
ETFs with the largest estimated holdings in INCY
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $INCY stock a Buy, Sell, or Hold?
- What is the price target for $INCY stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $INCY stock?
- Who owns the most shares of $INCY stock?
- What funds own $INCY stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view INCY Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
- Address Wilmington, DE
- Market Cap 24.9 billion
- Employees 2,844
- Industrial Classification Services-Commercial Physical & Biological Research
We estimate that -- received a compensation of -- in --, making them the highest paid executive at INCY, per a recent SEC DEF 14A filing. We estimate that the median employee at INCYTE CORP is paid $255,918.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|